tradingkey.logo

Venus Concept Inc

VERO

2.290USD

-0.050-2.14%
Close 09/19, 16:00ETQuotes delayed by 15 min
4.26MMarket Cap
LossP/E TTM

Venus Concept Inc

2.290

-0.050-2.14%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
136 / 207
Overall Ranking
353 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Venus Concept Inc. is a global medical technology company. The Company develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services and reaches over 60 countries and 10 direct markets. The Company’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Its treatments for hair loss are divided into non-surgical options and surgical procedures. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. Its systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family medicine and general practitioners and aesthetic medical spas.
Growing
The company is in a growing phase, with the latest annual income totaling USD 64.83M.
Fairly Valued
The company’s latest PE is -0.06, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 303.44K shares, increasing 19.56% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.97.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.08, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 15.69M, representing a year-over-year decrease of 5.37%, while its net profit experienced a year-over-year decrease of 41.25%.

Score

Industry at a Glance

Previous score
6.08
Change
0

Financials

4.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

6.89

Operational Efficiency

6.04

Growth Potential

6.13

Shareholder Returns

7.09

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -0.06, which is -3.11% below the recent high of -0.06 and -4424.91% above the recent low of -2.62.

Score

Industry at a Glance

Previous score
2.80
Change
1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 136/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

94
Total
4
Median
7
Average
Company name
Ratings
Analysts
Venus Concept Inc
VERO
2
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.50, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.71 and the support level at 2.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
3.50
Change
-0.06

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(4)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
0.025
Neutral
RSI(14)
46.000
Neutral
STOCH(KDJ)(9,3,3)
47.656
Sell
ATR(14)
0.105
Low Volatility
CCI(14)
45.361
Neutral
Williams %R
47.732
Neutral
TRIX(12,20)
-0.228
Sell
StochRSI(14)
12.573
Sell
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
2.320
Sell
MA10
2.299
Sell
MA20
2.313
Sell
MA50
2.416
Sell
MA100
2.428
Sell
MA200
2.987
Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 16.32%, representing a quarter-over-quarter decrease of 36.04%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Orca Capital GmbH
101.75K
--
EW Healthcare Partners
99.02K
+0.00%
HealthQuest Capital Management, L.P
41.19K
--
Madryn Asset Management, LP
10.19K
--
De Silva (Rajiv)
7.58K
--
Tower Research Capital LLC
1.78K
+176.28%
Hollmig (Stanley Tyler)
1.76K
--
Gunhus (Kirk)
1.64K
--
Varghese (Hemanth Jacob)
1.52K
+0.07%
Della Penna (Domenic)
918.00
--
1
2

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.05. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.05
Change
0
Beta vs S&P 500 index
0.05
VaR
+10.00%
240-Day Maximum Drawdown
+75.59%
240-Day Volatility
+222.45%
Return
Best Daily Return
60 days
+12.60%
120 days
+205.76%
5 years
+205.76%
Worst Daily Return
60 days
-12.88%
120 days
-54.55%
5 years
-54.55%
Sharpe Ratio
60 days
+0.65
120 days
+0.70
5 years
-0.06
Risk Assessment
Maximum Drawdown
240 days
+75.59%
3 years
+96.55%
5 years
+99.60%
Return-to-Drawdown Ratio
240 days
-0.77
3 years
-0.32
5 years
-0.20
Skewness
240 days
+8.71
3 years
+7.96
5 years
+8.29
Volatility
Realised Volatility
240 days
+222.45%
5 years
+171.81%
Standardised True Range
240 days
+19.16%
5 years
+434.80%
Downside Risk-Adjusted Return
120 days
+179.85%
240 days
+179.85%
Maximum Daily Upside Volatility
60 days
+72.92%
Maximum Daily Downside Volatility
60 days
+45.66%
Liquidity
Average Turnover Rate
60 days
+221.12%
120 days
+218.14%
5 years
--
Turnover Deviation
20 days
-96.66%
60 days
+26.20%
120 days
+24.50%

Peer Comparison

Healthcare Equipment & Supplies
Venus Concept Inc
Venus Concept Inc
VERO
4.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
8.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI